• K Stattin, M Lipcsey, H Andersson, E Pontén, S Bülow Anderberg, A Gradin, A Larsson, N Lubenow, M von Seth, S Rubertsson, M Hultström, and R Frithiof.
• Department of Surgical Sciences, Anesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden. Electronic address: karl.stattin@gmail.com.
• J Crit Care. 2020 Dec 1; 60: 249252249-252.

PurposeThe aim of this study was to investigate potential markers of coagulopathy and the effects of thromboprophylaxis with low-molecular-weight heparin (LMWH) on thromboelastography (TEG) and anti-factor Xa in critically ill COVID-19 patients.Material And MethodsWe conducted a prospective study in 31 consecutive adult intensive care unit (ICU) patients. TEG with and without heparinase and anti-factor Xa analysis were performed. Standard thromboprophylaxis was given with dalteparin (75-100 IU/kg subcutaneously).ResultsFive patients (16%) had symptomatic thromboembolic events. All patients had a maximum amplitude (MA) > 65 mm and 13 (42%) had MA > 72 mm at some point during ICU stay. Anti-factor Xa activity were below the target range in 23% of the patients and above target range in 46% of patients. There was no significant correlation between dalteparin dose and anti-factor Xa activity.ConclusionsPatients with COVID-19 have hypercoagulability with high MA on TEG. The effect of LMWH on thromboembolic disease, anti-factor Xa activity and TEG was variable and could not be reliably predicted. This indicates that standard prophylactic doses of LMWH may be insufficient. Monitoring coagulation and the LMWH effect is important in patients with COVID-19 but interpreting the results in relation to risk of thromboembolic disease poses difficulties.Copyright © 2020 Elsevier Inc. All rights reserved.

32 keywords...

hide…